Stock A228760 GENOMICTREE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genomictree Inc.

Equities

A228760

KR7228760005

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 26/06/2024 BST 		5-day change 1st Jan Change
24,350 KRW +10.18% Intraday chart for Genomictree Inc. +11.44% +18.20%
2023 Genomictree Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2022 Tranche Update on Genomictree Inc.'s Equity Buyback Plan announced on May 17, 2022. CI

Valuation

Fiscal Period: December 2019 2020 2021 2024 2025 2026
Capitalization 1 468,677 292,798 270,356 583,961 - -
Enterprise Value (EV) 2 369.6 206 270.4 544.6 555.3 556.2
P/E ratio -44 x -24.8 x -24.1 x -88.9 x 178 x 69 x
Yield - - - - - -
Capitalization / Revenue 1,664 x 236 x - 150 x 29.9 x 16.9 x
EV / Revenue 1,312 x 166 x - 140 x 28.5 x 16.1 x
EV / EBITDA - -17.9 x - -67.2 x 168 x 56.2 x
EV / FCF -33.8 x -16 x - -40.3 x -109 x 49.2 x
FCF Yield -2.96% -6.25% - -2.48% -0.92% 2.03%
Price to Book - 3.07 x - 4.95 x 4.82 x 4.5 x
Nbr of stocks (in thousands) 19,986 19,986 20,328 23,982 - -
Reference price 3 23,450 14,650 13,300 24,350 24,350 24,350
Announcement Date 16/03/20 09/03/21 18/03/22 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2024 2025 2026
Net sales 1 0.2816 1.239 - 3.9 19.5 34.5
EBITDA 1 - -11.5 - -8.1 3.3 9.9
EBIT 1 -10.31 -12.41 - -9.5 1.4 8.1
Operating Margin -3,660.17% -1,001.62% - -243.59% 7.18% 23.48%
Earnings before Tax (EBT) 1 -8.537 -11.72 - -6.3 3.1 9.7
Net income 1 -10.19 -11.8 -11.42 -6.6 3.3 8.5
Net margin -3,619.92% -952.1% - -169.23% 16.92% 24.64%
EPS 2 -533.0 -590.0 -553.0 -274.0 137.0 353.0
Free Cash Flow 3 -10,937 -12,871 - -13,500 -5,100 11,300
FCF margin -3,883,318.54% -1,038,909.1% - -346,153.85% -26,153.85% 32,753.62%
FCF Conversion (EBITDA) - - - - - 114,141.41%
FCF Conversion (Net income) - - - - - 132,941.18%
Dividend per Share - - - - - -
Announcement Date 16/03/20 09/03/21 18/03/22 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 99.1 86.8 - 39.4 28.7 27.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 2 -10,937 -12,871 - -13,500 -5,100 11,300
ROE (net income / shareholders' equity) -17% -11.6% - -5.4% 2.7% 6.7%
ROA (Net income/ Total Assets) - -10.2% - -5.2% 2.6% 6.3%
Assets 1 - 115.8 - 126.9 126.9 134.9
Book Value Per Share 3 - 4,766 - 4,920 5,057 5,410
Cash Flow per Share - - - - - -
Capex 1 2.24 2.68 - 4.6 9.3 -
Capex / Sales 796.23% 216.57% - 117.95% 47.69% -
Announcement Date 16/03/20 09/03/21 18/03/22 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENOMICTREE INC. Stock Genomictree Inc.
+18.20% 421M
MODERNA, INC. Stock Moderna, Inc.
+21.85% 46.44B
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.1B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.76B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.04% 31.24B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 25.8B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.65% 25.9B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+38.43% 13.12B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.92% 11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.29% 10.68B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A228760 Stock
  4. Financials Genomictree Inc.